PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sterilex Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Sterilex Corporation Appoints Mark E. Wozniak, Ph. D. as Director of Research and Development - Sterilex today announces that Mark E. Wozniak, Ph. D. has been appointed Director of Research and Development, effective immediately
Sterilex Corporation Appoints Mark E. Wozniak, Ph. D. as Director of Research and Development

 

NewswireToday - /newswire/ - Owings Mills, MD, United States, 2008/02/21 - Sterilex today announces that Mark E. Wozniak, Ph. D. has been appointed Director of Research and Development, effective immediately.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Prior to joining Sterilex, Dr. Wozniak held a variety of positions at J.M. Huber Corporation including Director of Quality and Senior R&D Manager. Dr. Wozniak is a proven leader in directing R&D initiatives and has experience guiding process improvement initiatives, leading business transformations and overhauling manufacturing procedures. At Sterilex, Dr. Wozniak will guide Sterilex’s R&D initiatives into safer, more effective anti-biofilm and antimicrobial technologies. He received his Bachelor of Science degree in Chemistry from the University of Michigan and his Ph. D. in Inorganic Chemistry from The Pennsylvania State University.

“We are very excited that Dr. Wozniak will be leading Sterilex’s innovation programs, and we look forward to working with him to continue Sterilex’s commitment to the development of innovative solutions for microbial control.” said Dr. Shira Kramer, President of Sterilex.

“I am honored by the opportunity to join the strong team at Sterilex and look forward to helping Sterilex develop innovative solutions that fortify its leadership position in markets it services.” Dr. Wozniak said.

About Sterilex Corporation

Sterilex Corporation (sterilex.com) is a leader in developing patented antimicrobial and anti-biofilm products for infection control, the decontamination of pathogens, spoilage organisms and resistant biofilms. The Sterilex product line includes EPA-registered antimicrobial products for biofilm and pathogen control, as well as specialty cleaning and decontaminating agents. Sterilex sells disinfectants, anti-biofilm biocides, cleaning, and decontaminating products to the health care, dental care, water care, industrial, food processing, and environmental remediation industries.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sterilex Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Sterilex Corporation Appoints Mark E. Wozniak, Ph. D. as Director of Research and Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alex Josowitz - Sterilex.com 
1-800-511-1659 alex[.]sterilex.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sterilex Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sterilex Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  1Click Games

Visit  Al Rowaad Advocates & Legal Consultants





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)